Next-generation sequencing
Next-generation sequencing

Unlock the potential of next-generation sequencing

Impactful discoveries powered by NGS

Next-generation sequencing (NGS) can deliver unprecedented insights, unraveling the intricacies of the genome and transcriptome in biomarker research, gene expression studies, viral epidemiology and disease surveillance, as well as comprehensive genomic profiling to identify variants implicated in cancer and other diseases. However, challenges such as workflow optimization, customization and data analysis and interpretation can hinder progress. Partner with QIAGEN to unlock the full potential of NGS with innovative QIAseq technologies.

Houston lab
Woman in lab smiling

Meet the recipients of the 2021 QIAGEN RNA-seq Grant

In 2021, we invited researchers to explore the potential of RNA-seq for their research by applying for a QIAGEN RNA-seq Grant. We received an astounding 2400 applications and are pleased to announce the grant recipients.

Enhance your core facility offering

Learn how our partnership with leading service centers and core labs overcome typical lab bottlenecks and advance your research.
two scientist in front of a monitor
Automate and accelerate your library prep
Automating your NGS means more consistency between runs, less batch processing errors, fewer re-runs, plus significant time and cost savings.
Stay up-to-date on all latest developments in NGS!
Sign up for the QIAGENomics newsletter and get updates sent to your inbox every month.
High-throughput genomic surveillance of emerging SARS-CoV-2 Delta, Mu and Omicron variants

The emergence of new, highly transmissible SARS-CoV-2 variants has elevated the need for high-throughput whole viral genome sequencing to accelerate genomic surveillance efforts. Cataloging new variants and evaluating the impact of the accumulated mutations is critical for vaccine development and effective public health measures. Explore how our high-performance, scalable NGS workflows with integrated bioinformatics facilitate accurate SARS-CoV-2 variant detection and phylogeographic tracking.

Corona virus
Go from RNA-seq to gene expression insights with ease

Struggling to make sense of your RNA-seq data? Take the stress out of data analysis and fast-track your path to gene expression insights with the new RNA-seq Analysis Portal. Designed for biologists and fully integrated with GeneGlobe, this intuitive, web-based solution is now included with QIAseq RNA-seq and miRNA-seq kits. Simply upload your sequence files into the RNA-seq Analysis Portal, start your analysis and go from FASTQ files to focused insights into the top 10 canonical pathways, upstream regulators and diseases using powerful IPA knowledge bases.

Expanding disease insights with exome sequencing

The coding portion of the genome holds tantalizing information on multiple diseases. Unlocking these details through exome sequencing can reveal powerful insights into disease-associated variants. However, coverage issues, long turnaround times and data analysis bottlenecks can diminish progress. Explore a time-saving workflow that seamlessly combines uniform exome coverage with streamlined secondary analysis, rapid variant filtering and annotation.

Explore benefits of QIAseq NGS
Get in touch to see how QIAseq NGS solutions can transform your research.
woman infront of a touchscreen
Accelerate integrated insights from NGS data with maximum ease
You’ve run your benchtop experiment and finally achieved NGS data. But what does it all mean? Demystify data analysis and interpretation with our intuitive bioinformatics tools.
Workflow Configurator, wfc, Luna
Check out the Workflow Configurator

This smart online tool can help you find the right products for every step of your workflow.

Useful resources to fuel your research

Without NGS, a modern laboratory is unimaginable today.
Prof. Paul Hofman, CHU Nice, France
  • Experiences with targeted sequencing
    Dr. Barnaby Clark, Laboratory Lead for Precision Medicine at Kings College Hospital NHS Foundation Trust, discusses his experiences with targeted sequencing and, ultimately, the choice of NGS panels for his projects.

  • Sequencing COVID-19 mutations after jumping species
    Dr. Mette Christiansen, Head of the Diagnostic NGS Core Facility, Molecular Medicine (MOMA) at Aarhus University Hospital, discusses the importance of sequencing every positive sample to develop a clear picture of circulating SARS-CoV-2 variants and how QIAseq NGS technologies facilitated these efforts.
  • Accelerating human and bacterial co-expression studies with high-quality RNA-seq data
    Dr. Marie Adams from the Van Andel Institute discusses how QIAseq FastSelect technology helped conquer the challenges of generating high-quality RNA-seq data for human and bacterial co-expression studies from the same RNA sample.
  • Increasing RNA-seq sensitivity in cancer research
    Researchers from the University of Houston discuss how powerful QIAseq FastSelect rRNA removal technology transformed their research, allowing them to retrieve useful RNA-seq data from FFPE RNA.
  • Defending against cancer by manipulating the immune system using NGS technology
    Dr. Nathalie Labarrière from the University of Nantes describes her work using QIAseq Immune Repertoire RNA Library Kits to target colon cancer and melanoma tumors in new immuno-oncology therapies.
  • Driving insights into pancreatic cancer risk using custom NGS panels
    Dr. Fergus Couch from the Mayo Clinic discusses how QIAseq Targeted DNA Panels played a vital role in a longitudinal case-control study on the risk of pancreatic cancer.
  • Ensuring uniform coverage enables heterozygous mutation detection in cancer research
    Dr. Egbert Schulze from the Endocrinology and Nuclear Medicine Community Practice, Heidelberg, discusses how the all-enzymatic QIAseq FX workflow enabled uniform coverage and helped him achieve reliable sequencing results in his research.
  • Dr Barnaby Clark
    Experiences with targeted sequencing
  • Genomics, QIAseq NGS Solutions, Dr. Mette Christiansen, Aarhus University hospital, COVID-1
    Sequencing COVID-19 mutations after jumping species
  • Marie Adams
    Accelerating human and bacterial co-expression studies with high-quality RNA-seq data
  • Asha Palat
    Increasing RNA-seq sensitivity in cancer research
  • Nathalie Labarriere
    Defending against cancer by manipulating the immune system using NGS technology
  • Dr. Fergus Couch
    Driving insights into pancreatic cancer risk using custom NGS panels
  • Egbert Schulze
    Ensuring uniform coverage enables heterozygous mutation detection in cancer research
All photos taken prior to COVID-19